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Abstract 
The aim of the present investigation was to prepare and evaluate cephalexin controlled release subgingival films using 
biodegradable sodium alginate. The equipment necessary for the present investigation was fabricated and employed for 
casting of sodium alginate subgingival films. Subgingival films of drug:polymer in various proportions (10:90, 25:75, 50:50 and 
75:25) were prepared using solvent casting method. A 10%w/v CaCl2 solution was used for gelation of the films. As polymer 
concentration is increased the smoothness of the films increased. The thickness of films varied from 146±5 to 312±15 µm 
which is well below the recommended thickness (<300 µm) of the subgingival films. The average weight of the films was found 
to be between 14.21±0.18 and 20.42 ±0.49. The percentage of drug content ranged from 53.14 to 56.81%. The low values 
may be due to loss of drug during treatment of the films with CaCl2 solution. In vitro release studies of all the films showed an 
initial burst release for the first 24 hrs, followed by controlled release of cephalexin (>0.24 µg/ml) up to 120 hrs which is 
sufficient to inhibit the growth of the micro-organisms. The rate of drug release was inversely proportional to polymer 
concentration in the formulations. The low K1 and ‘r’ values obtained may be due to biphasic drug release pattern. The 
formulations did not fit into Higuchi equation because of low values of <0.788025 which indicate that the drug release might be 
due to diffusion only in second phase of dissolution. All the films have shown to have integrity even after 5 days of dissolution 
studies. The formulations C1 and C2 which contain 90 and 75%w/w of polymer could be employed for controlled delivery of 
cephalexin for 5 days in subgingival infections. Sodium alginate, being a biodegradable polymer is a good choice as drug 
carrier in the present study. 
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Introduction 
Periodontitis is a tooth destructive disease that 
affects about 15% of the population [1]. Apart from scaling 
and planing, systemic antibiotic therapy is employed in 
treating periodontitis [2]. Systemic antimicrobial therapy 
requires high doses over a prolonged period to achieve 
required concentrations in the sulcular fluid which results 
in adverse effects. [3]. Development of local delivery 
devices which can be placed directly into the periodontal 
pocket promise a relief to the patient. These devices can 
maintain extremely high local concentrations of drug for 
period of up to one to two weeks. Several implantable 
devices like fibers [4], films [5, 6] and gels [7] were studied. 
Various biodegradable polymers such as poly(glycolideco 
dl-lactide) [8], polyester poly(-caprolactone) [9], glycerol 
monooleate [10], cross linked atelo-collagen [11], 
hydoxypropylcellulose [12, 13] were employed as drug 
carriers.  
The disadvantages of synthetic polymers insist 
the researcher to explore new avenues in drug delivery 
systems using natural biopolymers. Sodium alginate is 
natural hydrophilic, biodegradable [14, 15] polymer and 
has controllable porosity, bioadhesivity and 
biocompatibility. It has been used as controlled release 
drug delivery device [16-19] and employed to treat 
orthodontic constructions in periodontal diseases [20] and 
bone marrow implants [21]. Literature survey revealed that 
sodium alginate was not used as carrier in subgingival 
delivery.  
Cephalexin monohydrate is an oral 
semisynthetic first generation cephalosporin, effective 
against both gram-positive and gram-negative organisms 
[22, 23]. It is effective against Streptococcus mutans and 
Porphyromonas gingivalis that are present in periodontal 
infections [24, 25]. It is used in prophylaxis in dental 
procedures for individuals allergic to penicillins [26, 27]. 
Therefore cephalexin is a drug of choice for local delivery 
into subgingival cavity. The aim of the present 
investigation was to prepare and evaluate the controlled 
release subgingival films containing cephalexin using 
sodium alginate as carrier. 
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Materials and Methods 
Materials 
Cephalexin (as monohydrate) was gratis 
sample from Alkem Laboratories, Mumbai, India. 
Sodium alginate (200-600 cps and 120 mesh size), 
anhydrous calcium chloride, propylene glycol, 
monobasic potassium phosphate were purchased from 
BDH Chemicals Ltd., London.  
Spectrophotometric method for the estimation 
of cephalexin  
The spectrophotometric method reported by 
Patel et al [28] was modified by estimating cephalexin 
in pH 7.2 phosphate buffer. A stock solution containing 
100µg/mL cephalexin was prepared and scanned using 
UV-Visible spectrophotometer (Jenway 6505, UK, 
Sl.No. 2177) and the λmax and absorbance were 
measured. Further serial dilutions were made to obtain 
0.1 – 300 µg/mL of drug. Standard graph was 
constructed; the regression equation and correlation 
coefficients (r) were calculated using MS Excel 
software. 
Fabrication of equipment for preparation of 
films 
A glass plate with 1 ft side (1 sq ft size) and 
about ½ inch thickness was cut using glass cutter. The 
sides of the plate were ground so that it becomes 
smoother on all sides. Holes of 1/6 inch were bored on 
the four corners of the glass plate. Legs with adjustable 
screws were fixed to the glass plate (Fig. 4.1). The 
apparatus was leveled using a Spirit Leveller. A glass 
tube with 2 cm internal diameter (surface area of 3.142 
cm2) was cross-sectionally cut into pieces of 2 cm 
height and used for the casting of the subgingival films 
on the glass plate. Fevistick® paper glue was used to 
fix the die-tubes to the glass plate for temporary 
attachment during the process of casting of the films. 
Figure1. Fabricated glass plate used for casting of 
subgingival films 
 
 
 
 
 
 
 
Preparation of subgingival films 
The subgingival films of sodium alginate were 
prepared using solvent casting technique. The 
formulations containing drug:polymer ratios of 10:90, 
25:75, 50:50 and 75:25 were designed as summarized 
in Table 1. Sodium alginate was dissolved in deionized 
water in a glass bottle (5mL) by stirring for 1 h using a 
magnetic stirrer (Heidolph MR 3002, RPM 500, 
Germany) with 1cm Teflon® coated stirrer bar. 
Propylene glycol (10%w/w) was added to the bottle as 
a plasticizer. Then cephalexin was added to get 
required concentrations as above. After complete 
mixing, a 2 ml solution was poured into glass cylinder 
fixed on the fabricated glass plate placed on a 
horizontal plane. The glass plate was loosely covered 
so that the solvent (water) was allowed to evaporate 
slowly at 24° for 24-48 h. The casted films were 
collected after complete evaporation of the solvent. 
Then the films were placed separately in aluminum foil 
(domestic grade) cups of 2 cm diameter containing 
0.5ml solution of 10% calcium chloride so that they are 
immersed completely. The cups were left aside at room 
temperature for complete drying. Finally the dried films 
were cut into pieces of 0.5×0.7 cm (0.35 cm2) size and 
wrapped in an aluminium foil and stored in a desiccator 
at room temperature in a dark place until further 
studies. 
 
 
 
 
Table 1. Composition of cast subgingival films containing Cephalexin 
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Evaluation of subgingival films 
Various properties such as size, thickness, 
weight variation, folding fortitude, percentage moisture 
loss and content uniformity were determined on the 
formulations. The thickness was measured at 6 
locations on the films using micrometer (Mitutoyo, 
Japan) and the average value was noted. Individual 
weights of three films were measured on top loading 
electronic balance (Sartorius BP 310S, Germany) and 
the mean weight was measured. Folding fortitude was 
measured by repeatedly folding the film of 1×1 cm size 
at same place until it broke. Percentage moisture loss 
was determined by placing the film in a desiccator 
containing anhydrous calcium chloride. After 72 h, the 
films were weighed and the percentage moisture loss 
was calculated using the following formula. 
100
 wtInitial
 wtFinal - wt Initialloss %Moisture ×=  
Drug content estimation 
Three films were powdered using mortar and 
10 ml pH 7.2 phosphate buffer was added to dissolve 
the drug. The solution was filtered through Whatman 
No. 44 filter paper and cephalexin content was 
determined at λmax263 nm after suitable dilution using 
UV/Vis spectrophotometer. The extract of films without 
drug was used as blank.  
In vitro drug release studies 
The films (0.5×0.7 cm size) were placed 
separately in 5 ml glass vials with polyethylene cap 
containing 1 ml of pH 7.2 phosphate buffer. As the pH 
of crevicular fluids vary depending on pathological 
conditions, pH 7.2 was selected in the present study. 
The vials were placed in an incubator to maintain body 
temperature of 37oC during dissolution study. A 1mL of 
the buffer containing dissolved drug from the vial was 
withdrawn using a micropipette (Gilson 462046C, 
France) at time intervals of 1, 2, 4, 8, 12, 16, 24, 36, 48, 
72, 96 and 120 h. The sample was collected into a 
10mL volumetric flask and an equal volume (1mL) of 
fresh buffer was replaced immediately into the vial after 
the withdrawal of the sample. The drug content was 
estimated by measuring the absorbance after suitable 
dilutions at λmax263 nm using standard graph. The 
dissolution kinetics were calculated using Microsoft 
Excel Software. 
Stability Studies 
Stability studies were conducted by wrapping 
the films in triplicate (size 0.5 x 0.7 cm) in aluminium 
foils and placing them at room temperature (25±5oC), 
in oven (40±2oC) and in refrigerator (4±2oC) over a 
period of three months. The films were observed for 
physical changes like colour, texture, and drug content 
at periodical intervals of 10 days each. The change in 
absorbance of cephalexin was also studied during the 
study. 
Results and Discussion 
A modified UV method for cephalexin in pH 
7.2 phosphate buffer was developed. The λmax was 
found to be 263nm. From the standard graph the 
regression equation and correlation coefficient (r) were 
calculated and found to be y=0.028x+0.024 and 0.998 
respectively indicating good linear relationship between 
concentration and absorbance.  The Linearity was 
found to be 5-100 µg for cephalexin. The equipment 
necessary for the present investigation was 
successfully fabricated and employed for casting of 
sodium alginate subgingival films with the help of a 
mould made of glass cylinder which shows that such 
formulations could be prepared with an easy technique.  
All the prepared films were found to be uniform in 
thickness with rough to smooth surface as the polymer 
concentration increased. The granular nature of the 
films containing above 25% w/w of polymer was 
attributed to high concentration of the drug present on 
the surface of the films. Using of propylene glycol 
(10%w/w of polymer) as plasticizer contributed to the 
flexibility of the prepared films. The treatment of the 
films with a 10%w/v calcium chloride solution resulted 
in slightly wrinkled film structure upon drying to the 
formulations containing 90% of the polymer (Fig. 2). 
This may be due to the fact that the formulations 
containing high concentration of polymer which forms 
hydrogel when wetted and then upon drying might 
have resulted in formation of folds. All the formulations 
resulted in gelation of the film after converted into 
calcium alginate. 
Figure 2 Showing (a) the dried films of various 
formulations; (b) Dissolution vials 
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Table 2. Evaluation data of cephalexin subgingival films 
 
All the values are mean with ± standard deviation. 
# Each film has size of 0.5×0.7 cm 
* number of times folded. 
 
The film properties such as size, thickness, 
weight variation, percentage moisture loss and content 
uniformity were determined and summarized in Table 2. 
The thickness of films varied from 146±5 to 312±15 
µm which is well tolerated to the recommended 
thickness (<300 µm) of the subgingival films. The films 
can easily be inserted into the subgingival space for 
delivery of drug. The variation in thickness of the films 
may be due to change in drug content. The average 
weight of the films was found to be between 
14.21±0.18 and 20.42 ±0.49 mg. All the formulations 
exhibited uniform thickness with low standard deviation 
values. Folding fortitude of the films showed that as the 
polymer concentration increased the folding strength 
increased. The percent moisture loss after drying of the 
films was found to be between 7±1.4 and 16±4.5%. 
The high moisture content in the formulation C1 may 
be due to high polymer concentration. The percentage 
of drug content ranged from 53.14 to 56.81%. The low 
values may be due to loss of drug during treatment of 
the films with CaCl2 solution.  
In vitro release studies performed using pH 
7.2 phosphate buffer. All the films showed an initial 
burst release for the first 24 hrs, followed by controlled 
release of cephalexin (>0.24 g/ml) up to 120 hrs which 
is sufficient to inhibit the growth of the micro-organisms 
as reported by Higashi et al. (1990). The rate of drug 
release was inversely proportional to polymer 
concentration in the formulations. The rate of 
cephalexin release was more  in formulations 
containing low polymer concentration that might be due 
to formation of more pores and channels. 
The Figs. 3 and 4 summarize the release 
patterns and kinetics of drugs from alginate subgingival 
films. The log% of drug remaining vs time plots 
resulted in regression curves as shown in Fig. 4. The 
dissolution kinetic parameters are summarized in Table 
3. Higher drug release (>96.64%) was found from all 
the films after 120 h. The formulations followed First 
order release kinetics with K1 values from 0.013818 to 
0.043757 which may be due to biphasic drug release 
pattern. Half-life of drug release was found to be 
between 15.83 and 50.15 h. The correlation coefficient 
(r) is obtained from 0.8062 to 0.9116. The low ‘r’ values 
in the formulations may be due to biphasic drug 
release with initial sharp followed by plateau phase.  
 
Figure 3. Cumulative % of cephalexin remaining vs time 
from subgingival films showing formulations C1 (-♦-), C2 (-■-), 
C3 (-▲-) and C4 (-×-). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Log % of cephalexin remaining vs time from 
subgingival films showing formulations C1 (-♦-), C2 (-■-), C3 (-
▲-) and C4 (-×-). 
 
 
 
 
 
 
 
Formulation# Mean 
Thickness (µm) 
(n=6) 
Mean Average 
Weight (mg) (n=3) 
Drug Content (mg) 
(n=3) 
Drug 
Content % 
Folding 
fortitude* 
% Moisture 
Loss 
C1 146±5 14.24±0.18 1.26±0.41 56.76 46 16±4.5 
C2 166±14 15.21±1.04 3.153±0.12 56.81 35 13±2.8 
C3 243±9 19.96±1.31 7.241±0.08 65.23 29 9±3.2 
C4 312±15 20.42 ±0.49 8.847±0.28 53.14 19 7±1.4 
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Table 3. Dissolution kinetics of cephalexin subgingival films 
 
 
 
 
 
  
 
 
The formulations did not fit into Higuchi equation 
because of low values of <0.788025 which indicate that 
the drug release might be due to only diffusion in 
second phase of dissolution. All the films have shown 
to have integrity even after 5 days of dissolution 
studies which shows that the formed calcium alginate 
gel was strong enough to be placed in the subgingival 
cavity for sufficient period of time for controlled release 
of the cephalexin. During the stability studies the films 
did not show any significant change in physical 
properties. The drug content did not alter by more than 
4%. 
Conclusions 
Local subgingival controlled delivery of 
antibiotics using biodegradable polymers is of recent 
interest to the formulation scientist. The present 
investigation showed that the formulations C1 and C2 
which contain 90 and 75%w/w of polymer could be 
employed for controlled delivery of cephalexin for 5 
days in subgingival infections. Sodium alginate, being a 
biodegradable polymer is a good choice in the present 
study. It has other advantages like biocompatibility, 
natural origin, hydrogel-property and bioadhesivity 
which culminate to make this polymer a judicious 
choice as drug carrier for controlled release subgingival 
delivery films. 
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